Meeting
2022 ASCO Annual Meeting
Phase 1b/2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer.
Authors
Ching-Wen Huang
Division of Colorectal Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Ching-Wen Huang , Jaw-Yuan Wang , Chou-Pin Chen , Po-Li Wei , Huang-Ming Hu , Wen-Hung Hsu , Hsiang-Yao Shih , Ming-Yii Huang , Chiao-Yun Chen , Chao-Hung Kuo , Chou-Chen Chen , Tzu-Wei Chiang , Jeffrey Yung-Chuan Chao , You-Hsin Chiu , Cheng Tiong , Pao-Ying Lin , Long-Sheng Lu , Ching-Huei Kung , Wei-Che Yu , Yu-Shan Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT02465593
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3603)
DOI
10.1200/JCO.2022.40.16_suppl.3603
Abstract #
3603
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
First Author: Kristina Hoot Young
Poster
2021 Gastrointestinal Cancers Symposium
A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial.
First Author: Jaw-Yuan Wang
First Author: Steven J. Cohen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang